Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(0.39)
# 4,403
Out of 4,693 analysts
227
Total ratings
41.9%
Success rate
-4.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Reiterated: Buy | $19 → $29 | $14.58 | +98.90% | 6 | Sep 1, 2026 | |
| ANVS Annovis Bio | Reiterated: Buy | $8 → $7 | $1.69 | +314.20% | 2 | Aug 27, 2026 | |
| CAPR Capricor Therapeutics | Maintained: Hold | $7 | $10.01 | -30.07% | 18 | Aug 25, 2026 | |
| CING Cingulate | Rated: Buy | $10 → $9 | $5.11 | +76.13% | 26 | Aug 24, 2026 | |
| COYA Coya Therapeutics | Reiterated: Buy | $12 | $4.51 | +166.08% | 3 | Aug 23, 2026 | |
| PMN ProMIS Neurosciences | Rated: Buy | $30 → $29 | $13.35 | +117.23% | 3 | Aug 21, 2026 | |
| CRVO CervoMed | Maintained: Buy | $9 → $7 | $2.57 | +172.37% | 21 | Aug 20, 2026 | |
| LGVN Longeveron | Maintained: Buy | $3 | $6.75 | -55.56% | 17 | Aug 19, 2026 | |
| GANX Gain Therapeutics | Maintained: Buy | $8 | $1.77 | +351.98% | 29 | Aug 18, 2026 | |
| PYPD PolyPid | Rated: Buy | $9 → $8 | $5.33 | +50.09% | 21 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $11 | $7.07 | +55.59% | 22 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.4201 | +614.12% | 6 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $37 | $47.10 | -21.44% | 5 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 → $7 | $2.76 | +153.62% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $1 | $0.51 | +96.08% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.3881 | n/a | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.68 | n/a | 2 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.27 | n/a | 11 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $55.60 | n/a | 9 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $28.14 | n/a | 6 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.3 | $17.04 | n/a | 5 | Sep 19, 2023 |
Immunic
Sep 1, 2026
Reiterated: Buy
Price Target: $19 → $29
Current: $14.58
Upside: +98.90%
Annovis Bio
Aug 27, 2026
Reiterated: Buy
Price Target: $8 → $7
Current: $1.69
Upside: +314.20%
Capricor Therapeutics
Aug 25, 2026
Maintained: Hold
Price Target: $7
Current: $10.01
Upside: -30.07%
Cingulate
Aug 24, 2026
Rated: Buy
Price Target: $10 → $9
Current: $5.11
Upside: +76.13%
Coya Therapeutics
Aug 23, 2026
Reiterated: Buy
Price Target: $12
Current: $4.51
Upside: +166.08%
ProMIS Neurosciences
Aug 21, 2026
Rated: Buy
Price Target: $30 → $29
Current: $13.35
Upside: +117.23%
CervoMed
Aug 20, 2026
Maintained: Buy
Price Target: $9 → $7
Current: $2.57
Upside: +172.37%
Longeveron
Aug 19, 2026
Maintained: Buy
Price Target: $3
Current: $6.75
Upside: -55.56%
Gain Therapeutics
Aug 18, 2026
Maintained: Buy
Price Target: $8
Current: $1.77
Upside: +351.98%
PolyPid
Aug 14, 2026
Rated: Buy
Price Target: $9 → $8
Current: $5.33
Upside: +50.09%
Aug 12, 2026
Reiterated: Buy
Price Target: $10 → $11
Current: $7.07
Upside: +55.59%
Jun 10, 2026
Maintained: Buy
Price Target: $3
Current: $0.4201
Upside: +614.12%
May 18, 2026
Rated: Buy
Price Target: $31 → $37
Current: $47.10
Upside: -21.44%
May 14, 2026
Rated: Buy
Price Target: $5 → $7
Current: $2.76
Upside: +153.62%
Apr 1, 2026
Rated: Buy
Price Target: $30 → $1
Current: $0.51
Upside: +96.08%
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.3881
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.68
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $14.27
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $55.60
Upside: n/a
Oct 24, 2023
Maintained: Hold
Price Target: n/a
Current: $28.14
Upside: n/a
Sep 19, 2023
Reiterated: Hold
Price Target: $0.3
Current: $17.04
Upside: n/a